Antigenics Inc. (ANTI)
OTC GREY OTC GREY Primary Summary
ANTI Chart
Antigenics Inc. (ANTI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Antigenics Inc. ever had a stock split?
Antigenics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Garo Armen CEO | OTC GREY Exchange | 037031101 CUSIP |
| US Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Antigenics, Inc., positioned in Huntingdon Valley, Pennsylvania, is a biotechnology company committed to the discovery and development of innovative immunotherapies for a broad range of diseases. The company focuses on the creation of vaccines and therapies that stimulate the immune system to combat diseases more effectively. With a strong emphasis on research and innovation, Antigenics aims to advance the field of immunotherapy, providing new treatment options for patients worldwide.
Products and Services
- Vaccine Development
- Immunotherapy Treatments
At the core of Antigenics’ offerings is its vaccine development program. The company works on creating vaccines against infectious diseases, as well as therapeutic vaccines for treating cancer. Utilizing cutting-edge biotechnology, Antigenics is dedicated to developing vaccines that can offer long-term immunity and potentially transform the way diseases are treated and managed.
Antigenics is also engaged in the development of immunotherapy treatments aimed at enhancing the body's immune response to cancer. These treatments are designed to target and destroy cancer cells by strengthening the immune system's natural defense mechanisms. The goal of Antigenics' immunotherapy treatments is to achieve a more effective and less toxic response to cancer compared to traditional therapies.
